Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands.
Transl Psychiatry. 2020 Sep 29;10(1):332. doi: 10.1038/s41398-020-01018-7.
Developing Alzheimer's disease (AD) is influenced by multiple genetic variants that are involved in five major AD-pathways. Per individual, these pathways may differentially contribute to the modification of the AD-risk. The pathways involved in the resilience against AD have thus far been poorly addressed. Here, we investigated to what extent each molecular mechanism associates with (i) the increased risk of AD and (ii) the resilience against AD until extreme old age, by comparing pathway-specific polygenic risk scores (pathway-PRS). We used 29 genetic variants associated with AD to develop pathway-PRS for five major pathways involved in AD. We developed an integrative framework that allows multiple genes to associate with a variant, and multiple pathways to associate with a gene. We studied pathway-PRS in the Amsterdam Dementia Cohort of well-phenotyped AD patients (N = 1895), Dutch population controls from the Longitudinal Aging Study Amsterdam (N = 1654) and our unique 100-plus Study cohort of cognitively healthy centenarians who avoided AD (N = 293). Last, we estimated the contribution of each pathway to the genetic risk of AD in the general population. All pathway-PRS significantly associated with increased AD-risk and (in the opposite direction) with resilience against AD (except for angiogenesis, p < 0.05). The pathway that contributed most to the overall modulation of AD-risk was β-amyloid metabolism (29.6%), which was driven mainly by APOE-variants. After excluding APOE variants, all pathway-PRS associated with increased AD-risk (except for angiogenesis, p < 0.05), while specifically immune response (p = 0.003) and endocytosis (p = 0.0003) associated with resilience against AD. Indeed, the variants in these latter two pathways became the main contributors to the overall modulation of genetic risk of AD (45.5% and 19.2%, respectively). The genetic variants associated with the resilience against AD indicate which pathways are involved with maintained cognitive functioning until extreme ages. Our work suggests that a favorable immune response and a maintained endocytosis pathway might be involved in general neuro-protection, which highlight the need to investigate these pathways, next to β-amyloid metabolism.
阿尔茨海默病(AD)的发生受到多种基因变异的影响,这些变异涉及五个主要的 AD 通路。就个体而言,这些通路可能会对 AD 风险的改变产生不同的影响。迄今为止,针对 AD 抗性的相关通路仍未得到充分研究。在这里,我们通过比较特定于通路的多基因风险评分(pathway-PRS),来研究每个分子机制在多大程度上与(i)AD 风险增加和(ii)直至极端高龄的 AD 抗性相关。我们使用与 AD 相关的 29 个遗传变异来为五个与 AD 相关的主要通路开发 pathway-PRS。我们开发了一个整合框架,允许多个基因与一个变体相关,以及多个通路与一个基因相关。我们在经过充分表型分析的 AD 患者的阿姆斯特丹痴呆队列(N=1895)、来自阿姆斯特丹纵向老龄化研究的荷兰人群对照(N=1654)和我们独特的认知健康百岁以上研究队列(N=293)中研究了 pathway-PRS,这些队列中的人避免了 AD。最后,我们估计了每个通路对一般人群中 AD 遗传风险的贡献。所有的 pathway-PRS 都与 AD 风险增加显著相关(相反的方向与 AD 抗性相关)(除了血管生成,p<0.05)。对 AD 风险整体调节贡献最大的通路是β-淀粉样蛋白代谢(29.6%),这主要是由 APOE 变体驱动的。在排除 APOE 变体后,所有与 AD 风险增加相关的 pathway-PRS(除了血管生成,p<0.05),而免疫反应(p=0.003)和内吞作用(p=0.0003)与 AD 抗性相关。事实上,这两个通路中的变异成为 AD 遗传风险整体调节的主要贡献者(分别为 45.5%和 19.2%)。与 AD 抗性相关的遗传变异表明,哪些通路参与了认知功能在极端年龄下的维持。我们的工作表明,有利的免疫反应和维持的内吞作用途径可能与一般的神经保护有关,这突出了需要研究这些途径,除了β-淀粉样蛋白代谢。